ABSTRACT
Background: malignant pleural mesothelioma [MPM] represents a common malignant disease. It is an aggressive tumor arising from the mesothelial cells lining the pleura. There is an extremely poor prognosis and a vast majority of MPM patients are diagnosed in an advanced stage. Rapid progression of the disease, no effective therapeutic approach and resistance to chemotherapy and radiotherapy resulted in a median survival time of less than 12 months
Aim of the Work: this study aimed to analyze the clinic pathological profile, the various prognostic factors and treatment response of malignant mesothelioma patients in our center in terms of overall survival and progression free survival
Patients and Methods: this retrospective was conducted on Malignant Mesothelioma patients who presented to the Department of Clinical Oncology, Ain Shams University from 1 January, 2011 to 31 December, 2014
Results: the mean age of the included patients were 61.04 years with male predominance 50.6% and female 49.1%. Occupational risk was documented in only 11.1% of included patients; most patients live in the industrial environment [67.9%] and the rest in non industrial environment [32.1%]. All patients had negative family history of cancer. All patients had negative surgical history, 66.7% of patients had positive history of asbestos exposure. The commonest co morbidity among the studied patients were HTN as it was accounted for 24.7% of the included patients followed by diabetes mellitus in 16% of patients on the other hand, only 3.7% of patients had no co morbidity. Dyspnea was the commonest symptoms [77.8%] among the included patients, followed by cough [33.3%] and chest pain in 12.3%, the other symptoms with lower presentation included hemoptysis and anemia. P.S 1[28.4%] was recorded among the included patients and 53.1% patients had P.S 2 while, rest of patients 18.5% had P.S3. Patients were diagnosed by CT chest and pleural biopsy either US guided or CT guided, chest X ray, thoracoscopic biopsy, FNAC and open pleural biopsy. The results also showed that the median PFS among the included patients was 2 months. Median OAS was 6.1 months
Conclusion: best survival data in patients with MPM were currently reported from groups using multimodality treatment including MCR achieved either by EPP or extrapleural decortication for patients qualifying as far as tumor stage and functional reserve were concerned. In general, several treatment combinations have been applied ranging from systemic [neo- or adjuvant] to localized chemotherapy, neo- or adjuvant radiotherapy and others
Recommendations: The choice of the surgical procedure should be tailored according to tumor stage, performance status, and institutional experience. Morbidity and mortality of these treatment approaches have been reduced at experienced centers indicating that this complex treatment should be performed at dedicated high volume mesothelioma centers
ABSTRACT
Background: multiple myeloma [MM] is a malignant neoplasm of plasma cells that accumulate in bone marrow leading to bone destruction and marrow failure. Multiple myeloma accounts for about 1.8% of all cancers and slightly over 17% of all the hematologic malignancies in the United States. It is more common in men and for unknown reasons
Objective: this study aims at analysis the epidemiological data of the patients treated from multiple myeloma at Ain Shams University together with reviewing the different lines of management according to recent recommendations
Patients and Methods: this retrospective analysis of 62 patients with multiple myloma data recorded at their files with follow up and reviews of the recent advances in the management of multiple myeloma
Results: we found that 96.8% of patients showing clinical improvement after treatment on other hand only 3.2% deteriorated, 61.35 of patients were alive, 9.7% died and 29% lost follow up, the mean time to DFS was 22.55 months, mean OS was 63.2 months with 87.8% of patients survived at the end of the study, as regard mean PFS was 54.9 months with PFS at end of study was 74.9% of patients, there was insignificant differences between OS and demographic data, laboratory studies, there was insignificant differences between PFS and demographic data, laboratory studies
Conclusion: Multiple myeloma [MM] is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease